Freezing treatment plus immunotherapy and a pill for liver cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests whether freezing (cryoablation) combined with tislelizumab and lenvatinib can help shrink advanced liver cancer and improve outcomes after earlier treatments stopped working or caused side effects. It may be an option if your cancer can’t be removed with surgery and you’ve already tried one prior systemic (whole-body) treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re an adult (age 18 or older).
- You have confirmed advanced liver cancer that cannot be surgically removed (unresectable) or has spread (metastatic).
- Your cancer got worse or you couldn’t tolerate one prior whole-body treatment for advanced liver cancer.
- You have at least one measurable tumor spot that can be tracked by CT or MRI scans.
- Your body can handle treatment: blood counts, liver tests, and kidney tests are within required limits, and you can do usual activities (ECOG 0–2).
- You can follow the study plan, including visits, scans, and using birth control if needed.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether a combination of the drug lenvatinib, a liver treatment called TACE, and the immunotherapy drug camrelizumab can shrink advanced hepatocellular carcinoma enough to make surgery (or “conversion resection”) possible. It may help some people live longer by improving the chance that the cancer can be removed.
This trial tests whether freezing (cryoablation) liver metastases works better when combined with immunotherapy (sintilimab) and a targeted pill (lenvatinib). It’s for people whose cancer has spread to the liver and has not responded to earlier treatments.
This Phase 2 trial tests whether freezing (cryoablation) plus sintilimab (an immune system medicine) and regorafenib (a pill) can shrink colorectal cancer that has spread to the liver. It is for people whose cancer has come back or progressed after at least two prior chemotherapy treatments.
This trial tests if freezing tumor cells (cryoablation) combined with two drugs (tislelizumab and lenvatinib) can help people whose solid tumors have stopped responding to standard treatments. The goal is to see if this combination can shrink tumors or slow their growth.
This Phase 2 trial tests whether freezing part of the liver tumor (cryoablation) combined with an immunotherapy drug called anti–PD-1 can shrink advanced bile-duct cancer that can’t be removed by surgery. It may help control the cancer after prior treatments have stopped working.
This trial tests whether a combination of cryoablation (freezing tumors) and two drugs (lenvatinib and tislelizumab) works better than a standard chemotherapy regimen (FOLFOX) for people with advanced intrahepatic cholangiocarcinoma (a type of bile duct cancer in the liver) that has not responded to or has stopped responding to one prior therapy.
Hear when a new Advanced Hepatocellular Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.